ZEALAND PHARMA A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 611 DKK | +5.07% |
|
+0.99% | +63.72% |
| Apr. 04 | U.S. Futures Up, European Stocks Flat as Powell Reiterates Room for Rate Cuts This Year | DJ |
| Mar. 20 | Zealand Pharma A/S Approves Appointments to the Board | CI |
| Sales 2024 * | 693M 99.39M | Sales 2025 * | 1.14B 163M | Capitalization | 36.21B 5.19B |
|---|---|---|---|---|---|
| Net income 2024 * | -358M -51.34M | Net income 2025 * | -254M -36.43M | EV / Sales 2024 * | 48.4 x |
| Net cash position 2024 * | 2.69B 385M | Net cash position 2025 * | 2.77B 398M | EV / Sales 2025 * | 29.3 x |
| P/E ratio 2024 * |
-101
x | P/E ratio 2025 * |
-1,140
x | Employees | 253 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.25% |
More Fundamentals
* Assessed data
More news
Latest transcript on Zealand Pharma A/S
More press releases
More news
| 1 day | +5.16% | ||
| 1 week | +0.99% | ||
| Current month | -10.34% | ||
| 1 month | -12.96% | ||
| 3 months | +36.26% | ||
| 6 months | +106.00% | ||
| Current year | +63.72% |
1 week
576.00
613.50
1 month
576.00723.50
Current year
342.20749.00
1 year
212.20749.00
3 years
69.55749.00
5 years
69.55749.00
10 years
58.00749.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 09-12-31 | |
| Director of Finance/CFO | - | 22-10-31 | |
Ivan M. Møller
COO | Chief Operating Officer | 52 | 18-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leonard Kruimer
BRD | Director/Board Member | 66 | 19-04-03 |
| Chairman | 69 | 14-12-31 | |
Kirsten Drejer
BRD | Director/Board Member | 68 | 18-04-18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 773 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 611 | +5.07% | 225 401 |
| 24-04-22 | 581.5 | -0.34% | 144,994 |
| 24-04-19 | 583.5 | -2.42% | 154,986 |
| 24-04-18 | 598 | -0.08% | 153,865 |
| 24-04-17 | 598.5 | -1.07% | 203,665 |
Delayed Quote Nasdaq Copenhagen, April 23, 2024 at 10:59 am EDT
More quotes
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Calendar
2024-05-16
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
581.5
DKK
Average target price
754.3
DKK
Spread / Average Target
+29.71%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +63.72% | 5.17B | |
| -0.10% | 103B | |
| +3.27% | 96.73B | |
| +1.92% | 21.31B | |
| -15.49% | 21.21B | |
| -6.82% | 18.79B | |
| -41.41% | 16.37B | |
| -22.01% | 13.68B | |
| +6.02% | 13.44B | |
| +23.87% | 10.98B |
- Stock Market
- Equities
- ZEAL Stock
